Internal Reference Number: FOI_6830
Date Request Received: 19/10/2022 00:00:00
Date Request Replied To: 25/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast cancer
Request Category: Companies
Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Lapatinib • Neratinib • Parp Inhibitors (Olaparib/Talazoparib) • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pembrolizumab • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Taxane and/or Anthracycline in combination • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
Answer To Question 1: Q. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) <5 • Abemaciclib + Fulvestrant <5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 • Atezolizumab +Nab-paclitaxel/Paclitaxel <5 • Capecitabine as a single agent 13 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane 0 • Fulvestrant as a single agent <5 • Lapatinib 0 • Neratinib <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 38 • Palbociclib + Fulvestrant 6 • Pembrolizumab 0 • Platinum (e.g. carboplatin or cisplatin) as a single agent <5 • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Ribociclib + Fulvestrant 0 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 5 • Taxane and/or Anthracycline in combination 6 • Trastuzumab as a single agent or in combination 47 • Trastuzumab emtansine 5 • Transtuzumab deruxtecan <5 • Any other active systemic anti-cancer therapy 6 | |
Question Number 2: Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part. | |
Answer To Question 2: SFT is currently participating in 8 Research studies related to breast cancer. 3 are open to recruitment. 5 are in follow up. 5 are interventional trials. 3 are observational studies. Please see attached Word document for study names and numbers of SFT patients involved. | |
Please see Attachments: | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.